Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 4/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27774525 | 0.90 | DHODH (0.53) | ALDH1A1HPGDJAK2JAK3DHODH | |
| SCHEMBL2923794 | 0.84 | POLQ (0.46) | ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL269345 | 0.84 | KDM4E (0.52) | ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL7128610 | 0.83 | KDM4E (0.44) | ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL13176308 | 0.83 | DHODH (0.46) | ALDH1A1HPGDSMN1; SMN2JAK2JAK3 | |
| SCHEMBL7076404 | 0.83 | KDM4E (0.44) | ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL7160789 | 0.83 | KDM4E (0.44) | ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL7160562 | 0.81 | HCRTR1 (0.48) | ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL496791 | 0.81 | KDM4E (0.71) | ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL7071013 | 0.80 | ALDH1A1 (0.47) | ALDH1A1HPGDKDM4ESMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
| EP-2079690-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008038251-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | ALDH1A1 702/4885HPGD 1029/4885KDM4E 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.